Capsida Reports Patient Death in Gene Therapy Trial
Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy.
Capsida Reports Patient Death in Gene Therapy Trial Read More »
Capsida has yet to disclose the exact cause of death. The patient had received the gene therapy CAP-002 for a type of epilepsy.
Capsida Reports Patient Death in Gene Therapy Trial Read More »
New York City has seen increased life sciences employment during the past decade as public funding and key projects like JLABS @ NYC have given the area a boost. A Partnership Fund for New York City executive discusses the city’s strengths and a notable challenge facing businesses.
New York City’s Life Sciences Scene Grows in Stature Read More »
The influential senator argued the technology giant delivered “dangerous, insecure software” to the health system that contributed to a massive cyberattack last year.
Wyden urges FTC to investigate Microsoft over Ascension cyberattack Read More »
Analysts at BMO Capital Markets expect the lack of other exon-44-skiping therapies to facilitate a “smooth” approval process for Avidity’s del-zota.
Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA Read More »
New draft guidelines suggest the FDA is open to exercising regulatory flexibility for non-opioid drugs being developed for chronic pain.
FDA Looks to Streamline Development of Non-Opioid Painkillers Read More »
Claiming that the domestic market undervalues pharma innovation, Merck has decided to pull the plug on all of its R&D efforts in the U.K.
Merck Abandons $1.3B R&D Center in London, Boots 125 Employees Read More »
La empresa moderna pide foco. Pide velocidad. Pide sistemas que no fallen. Soft2Bet responde con una plataforma firme y dúctil. La base es clara. Tecnología que encaja. Operativa que fluye. Resultados que se miden. Aquí verás cómo su propuesta eleva el rendimiento …
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. This webinar will show leaders how strategic insights and targeted outreach can turn awareness into high-converting leads. Watch now.
2026 will mark the fourth consecutive year of substantial health benefit cost growth, signaling “mounting pressure on employers’ healthcare budgets.”
Health benefit cost increases expected to hit 15-year high, Mercer warns Read More »
The autoimmune and inflammatory disease–focused company canceled plans to go public earlier this year as the IPO window slammed shut.
Odyssey Rebounds Off Failed IPO With $213M Series D Read More »